Souhaitez-vous accéder aux communiqués récents ?

FDA endorses key elements of Arletta Pharma's Phase 2 study of Lybrido, a dual-action therapy for women with FSIAD/HSDD, and opens path to a single Phase 3

Washington, DC, July 15, 2026 (GLOBE NEWSWIRE) -- The Association of Clinical Research Professionals (ACRP) today announced that all ACRP Certification examinations will transition to the...

Dublin, July 15, 2026 (GLOBE NEWSWIRE) -- The "Clinical Trials Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global clinical trials market is forecast to expand...

호주 아들레이드, July 10, 2026 (GLOBE NEWSWIRE) -- 호주에 본사를 둔 글로벌 임상시험수탁기관(CRO)인 아반스 클리니컬(Avance Clinical)은 7월 15일부터 19일까지 대만 타이베이 난강전시센터(Taipei Nangang Exhibition Center, TaiNEX)에서 열리는 'BIO Asia–Taiwan...

Avance Clinical to Showcase Asia and China Growth Strategy at BIO Asia–Taiwan 2026

Avance Clinical to Showcase Asia and China Growth Strategy at BIO Asia–Taiwan 2026

Quoin Pharmaceuticals (NASDAQ: QNRX) receives FDA IND clearance for a Phase 2 study of QRX003 in Peeling Skin Syndrome, with initiation expected in 2H 2026

Tekton Research, a multi-specialty clinical research site organization, is expanding its partnership with Summit Clinical Research Solutions (“Summit”).

SplashBIO™ brings biomarker pre-screening to the front of the clinical trial — built to reduce screen failures and accelerate enrollment.

– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol — – FDA agreed that a single pivotal Phase 3...